Xilio Therapeutics promotes Martin Huber to President; appoints Robert Ross to Board

Xilio Therapeutics, Inc.

Martin Huber promoted to President, continues as head of R&D; new employment agreement with $500k base salary and 50% target bonus.
Huber granted option to purchase 20,000 shares of common stock, vesting over 4 years in equal monthly installments.
Robert Ross, M.D., appointed to Board as Class II director effective June 15, 2022; also joins Compensation Committee.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Ross

Class II director

XLO · Xilio Therapeutics, Inc.

Effective: 2022-06-15
Filed: June 16, 2022, 7:59 PM ET

Effective June 15, 2022, the Board, on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Ross, M.D. to the Board as a Class II director of the Company

Role change

Martin Huber

President

XLO · Xilio Therapeutics, Inc.

Effective: 2022-06-15
Filed: June 16, 2022, 7:59 PM ET

On June 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) promoted Martin Huber, M.D., 62, to President of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Ross was appointed as Class II director at Xilio Therapeutics, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

Effective June 15, 2022, the Board, on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Ross, M.D. to the Board as a Class II director of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Huber changed role as President at Xilio Therapeutics, Inc..

Action: promoted
Role: President

Exact text from the filing

On June 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) promoted Martin Huber, M.D., 62, to President of the Company.

View on SEC.gov

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-010062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.